Option Care Health, Inc. (NASDAQ:OPCH) Receives $33.00 Average PT from Brokerages

Option Care Health, Inc. (NASDAQ:OPCH - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight analysts that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $33.00.

A number of brokerages have weighed in on OPCH. Jefferies Financial Group raised shares of Option Care Health from a "hold" rating to a "buy" rating and increased their target price for the stock from $26.00 to $35.00 in a report on Thursday, January 23rd. JMP Securities restated a "market outperform" rating and issued a $30.00 price target (down previously from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. JPMorgan Chase & Co. boosted their price target on shares of Option Care Health from $40.00 to $41.00 and gave the company an "overweight" rating in a report on Thursday, March 6th. Barrington Research upped their price target on Option Care Health from $33.00 to $38.00 and gave the stock an "outperform" rating in a research note on Thursday, February 27th. Finally, Bank of America upgraded shares of Option Care Health from a "neutral" rating to a "buy" rating and upped their target price for the company from $26.00 to $33.00 in a research note on Monday, January 13th.

Option Care Health Trading Down 2.0 %

Shares of OPCH stock traded down $0.67 on Thursday, reaching $32.87. 2,353,635 shares of the stock were exchanged, compared to its average volume of 1,736,934. The company has a quick ratio of 1.32, a current ratio of 1.73 and a debt-to-equity ratio of 0.77. Option Care Health has a 1-year low of $21.39 and a 1-year high of $35.53. The firm has a 50 day moving average of $33.00 and a two-hundred day moving average of $28.50. The stock has a market cap of $5.40 billion, a P/E ratio of 27.62, a price-to-earnings-growth ratio of 2.30 and a beta of 1.07.

Remove Ads

Insiders Place Their Bets

In other Option Care Health news, insider Michael Bavaro sold 30,996 shares of the firm's stock in a transaction on Friday, February 28th. The shares were sold at an average price of $33.26, for a total value of $1,030,926.96. Following the sale, the insider now owns 44,974 shares of the company's stock, valued at $1,495,835.24. This trade represents a 40.80 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.64% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Option Care Health

Hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP increased its holdings in Option Care Health by 84.6% during the fourth quarter. Wellington Management Group LLP now owns 18,325,123 shares of the company's stock valued at $425,143,000 after buying an additional 8,400,208 shares during the last quarter. Norges Bank purchased a new position in Option Care Health during the fourth quarter worth $60,219,000. Voloridge Investment Management LLC purchased a new stake in shares of Option Care Health in the fourth quarter worth approximately $27,428,000. Freestone Grove Partners LP purchased a new position in shares of Option Care Health during the fourth quarter worth approximately $17,487,000. Finally, Dimensional Fund Advisors LP increased its stake in shares of Option Care Health by 17.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 3,988,051 shares of the company's stock valued at $92,518,000 after buying an additional 591,042 shares during the period. Institutional investors own 98.05% of the company's stock.

Option Care Health Company Profile

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.